Some studies (Wei, et al., 2022) have found that the core target of BG in the treatment of NAFLD is AKT1, and it has a good binding affinity with ginsenosides, the main component of BG, and experimental verification has found that BG administration can improve the liver histological changes induced by methionine and choline deficiency diet. Here, AKT1 is linked to metabolic dysfunction-associated steatotic liver disease.